Novo Nordisk
Page 5 of 9
FinanceSwiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By Prarthana PrakashJuly 29, 2024
RetailAn obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value
By Naomi Kresge, Lisa Pham and BloombergJuly 23, 2024
HealthPharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By Damian Garde and BloombergJuly 11, 2024
FeaturesOzempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By Jessica Mathews and Alena BotrosJuly 9, 2024
HealthFake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By Amanda LoudinJune 27, 2024
HealthA rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails
By Naomi Kresge and BloombergJune 27, 2024
HealthEU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
By Naomi Kresge and BloombergJune 26, 2024
By Lionel LimJune 26, 2024
HealthNovo Nordisk plots $4.1 billion in U.S. factory amid Ozempic shortage, the same day it pulled out of its Ireland development project
By Naomi Kresge and BloombergJune 25, 2024
RetailOzempic is 1,300% more expensive in the U.S. vs the U.K.—so the boss of Novo Nordisk is being hauled in front of Bernie Sanders to explain why
By Ryan HoggJune 17, 2024
RetailDanish pharma giant Novo Nordisk’s office building is in danger of collapsing after a ‘massive fire’ broke out
By Sanne Wass, Naomi Kresge and BloombergMay 23, 2024
RetailNestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
By Sasha RogelbergMay 21, 2024
FinanceDenmark’s economy shrinks 1.8% on reduced pharma production, showing extent of Novo Nordisk dependency
By Sanne Wass and BloombergMay 21, 2024
Most Popular
